AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38302990 — intervention group
Group type: COMPARATOR
Intervention: Habitual/Western dietary pattern
Number of subjects: 0
Study 38302995 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MD)
Number of subjects: 52
Study 38302995 — intervention group
Group type: EXPERIMENTAL
Intervention: lacto-ovo vegetarian diet (VD)
Number of subjects: 52
Study 38303009 — intervention group
Group type: EXPERIMENTAL
Intervention: E-bibliotherapy
Number of subjects: 192
Study 38303009 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 192
Study 38303019 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus a comprehensive tailored rehabilitation intervention focusing on supporting return to work (RTW)
Number of subjects: 0
Study 38303019 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 38303550 — intervention group
Group type: EXPERIMENTAL
Intervention: Transitional care model with month-long nurse-led home visits and long-term heart function clinic visits
Number of subjects: 2494
Study 38303550 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2494
Study 38303550 — intervention group
Group type: EXPERIMENTAL
Intervention: Transitional care model
Number of subjects: 2494
Study 38303653 — intervention group
Group type: EXPERIMENTAL
Intervention: High risk of sleep apnea
Number of subjects: 0
Study 38303926 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean dietary intervention (without personalized meal planning)
Number of subjects: 155
Study 38303926 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (no intervention)
Number of subjects: 155
Study 38303926 — intervention group
Group type: EXPERIMENTAL
Intervention: NAFLD patients
Number of subjects: 155
Study 38303926 — intervention group
Group type: EXPERIMENTAL
Intervention: NAFLD patients with mild steatosis
Number of subjects: 155
Study 38304039 — intervention group
Group type: EXPERIMENTAL
Intervention: T+N (toripalimab + nab-paclitaxel)
Number of subjects: 531
Study 38304039 — intervention group
Group type: COMPARATOR
Intervention: P+N (placebo + nab-paclitaxel)
Number of subjects: 531
Study 38304039 — intervention group
Group type: EXPERIMENTAL
Intervention: T+N (toripalimab + nab-paclitaxel) with 80% reimbursement
Number of subjects: 531
Study 38304039 — intervention group
Group type: COMPARATOR
Intervention: P+N (placebo + nab-paclitaxel) with 80% reimbursement
Number of subjects: 531
Study 38304225 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 565
Study 38304225 — intervention group
Group type: COMPARATOR
Intervention: Phentermine 30 mg
Number of subjects: 565
Study 38304225 — intervention group
Group type: EXPERIMENTAL
Intervention: PHEN/TPM (15 mg/92 mg)
Number of subjects: 565
Study 38304225 — intervention group
Group type: COMPARATOR
Intervention: PHEN/TPM vs Placebo
Number of subjects: 565
Study 38304225 — intervention group
Group type: COMPARATOR
Intervention: PHEN/TPM vs Phentermine 30 mg
Number of subjects: 565
Study 38304227 — intervention group
Group type: EXPERIMENTAL
Intervention: e-HOPE (online caregiver education resource)
Number of subjects: 16
Study 38304609 — intervention group
Group type: EXPERIMENTAL
Intervention: Faricimab
Number of subjects: 5000
Study 38304609 — intervention group
Group type: EXPERIMENTAL
Intervention: Port Delivery System (PDS) with ranibizumab
Number of subjects: 5000
Study 38304609 — intervention group
Group type: EXPERIMENTAL
Intervention: PDS
Number of subjects: 5000
Study 38304609 — intervention group
Group type: EXPERIMENTAL
Intervention: Faricimab and PDS
Number of subjects: 5000
Study 38304733 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple micronutrient-fortified bouillon cubes (upper-level)
Number of subjects: 0
Study 38304733 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple micronutrient-fortified bouillon cubes (lower-level)
Number of subjects: 0
Study 38304733 — intervention group
Group type: COMPARATOR
Intervention: Bouillon cube fortified with iodine only (control)
Number of subjects: 0
Study 38304743 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoimmunotherapy (sintilimab combined with nab-paclitaxel and carboplatin) for 2-3 cycles prior to surgical resection.
Number of subjects: 30
Study 38304826 — intervention group
Group type: EXPERIMENTAL
Intervention: Effector (E) GTA002 cells at E:T ratios of 10:1, 3:1, 1:1
Number of subjects: 0
Study 38304826 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow cytometry panels for NK cell potency assessment
Number of subjects: 0
Study 38305104 — intervention group
Group type: EXPERIMENTAL
Intervention: High FVIII/PC ratio on postoperative day 2
Number of subjects: 51
Study 38305104 — intervention group
Group type: EXPERIMENTAL
Intervention: High FVIII/PC ratio
Number of subjects: 51
Study 38305278 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocuff with AI
Number of subjects: 682
Study 38305278 — intervention group
Group type: EXPERIMENTAL
Intervention: AI alone
Number of subjects: 682
Study 38305278 — intervention group
Group type: COMPARATOR
Intervention: Standard high-definition (HD) colonoscopy
Number of subjects: 682
Study 38305378 — intervention group
Group type: EXPERIMENTAL
Intervention: Ridinilazole (200 mg twice daily for 10 days)
Number of subjects: 0
Study 38305378 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin (125 mg 4 times daily for 10 days)
Number of subjects: 0
Study 38305378 — intervention group
Group type: EXPERIMENTAL
Intervention: Ridinilazole
Number of subjects: 0
Study 38305378 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 0
Study 38305420 — intervention group
Group type: EXPERIMENTAL
Intervention: EDOF intraocular lens (IOL) in the dominant eye
Number of subjects: 37
Study 38305420 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-IOL in the nondominant eye
Number of subjects: 37
Study 38305420 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined EDOF/CT-IOL approach
Number of subjects: 37
Study 38305478 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracanalicular dexamethasone 0.4 mg
Number of subjects: 30
Study 38305478 — intervention group
Group type: COMPARATOR
Intervention: Topical prednisolone acetate (PA) 1%
Number of subjects: 30
Study 38305707 — intervention group
Group type: EXPERIMENTAL
Intervention: ITGA (Intubated General Anesthesia)
Number of subjects: 61
Study 38305707 — intervention group
Group type: COMPARATOR
Intervention: NMB (Neuromuscular Blocking)
Number of subjects: 61
Study 38305707 — intervention group
Group type: EXPERIMENTAL
Intervention: NB (Superior Laryngeal Nerve Block)
Number of subjects: 61
Study 38305868 — intervention group
Group type: EXPERIMENTAL
Intervention: Giredestrant
Number of subjects: 179
Study 38306042 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard BP treatment
Number of subjects: 457
Study 38306042 — intervention group
Group type: COMPARATOR
Intervention: Intensive BP treatment
Number of subjects: 457
Study 38306042 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 457
Study 38306042 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean BP
Number of subjects: 457
Study 38306312 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate supplementation
Number of subjects: 20
Study 38306312 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 38306343 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIE (8x4 min cycling bouts at 85% of VO2peak)
Number of subjects: 8
Study 38306343 — intervention group
Group type: COMPARATOR
Intervention: CON (matched kJ production from HIIE at 50% of VO2peak)
Number of subjects: 8
Study 38306343 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIE
Number of subjects: 8
Study 38306389 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast (10 mg)
Number of subjects: 358
Study 38306389 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 358
Study 38306602 — intervention group
Group type: EXPERIMENTAL
Intervention: MLLT10 fusions (n=127)
Number of subjects: 2080
Study 38306602 — intervention group
Group type: EXPERIMENTAL
Intervention: KMT2A::MLLT10 (n=104)
Number of subjects: 2080
Study 38306602 — intervention group
Group type: EXPERIMENTAL
Intervention: PICALM::MLLT10 (n=13)
Number of subjects: 2080
Study 38306745 — intervention group
Group type: EXPERIMENTAL
Intervention: Delandistrogene moxeparvovec gene therapy
Number of subjects: 0
Study 38306745 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids (additional administration starting one day preinfusion)
Number of subjects: 0
Study 38306745 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring liver function, troponin-I levels, and platelet counts postinfusion
Number of subjects: 0
Study 38306883 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mL/day EVOO
Number of subjects: 52
Study 38306883 — intervention group
Group type: COMPARATOR
Intervention: Control (usual diet and no supplemental EVOO)
Number of subjects: 52
Study 38306892 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycoprotein-containing food products (MYC)
Number of subjects: 72
Study 38306892 — intervention group
Group type: COMPARATOR
Intervention: Meat/fish control products (CON)
Number of subjects: 72
Study 38306953 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 38307098 — intervention group
Group type: EXPERIMENTAL
Intervention: 927 mg subcutaneous lenacapavir plus 30 mg/kg intravenous teropavimab and 10 mg/kg intravenous zinlirvimab
Number of subjects: 21
Study 38307098 — intervention group
Group type: EXPERIMENTAL
Intervention: 927 mg subcutaneous lenacapavir plus 30 mg/kg intravenous teropavimab and 30 mg/kg intravenous zinlirvimab
Number of subjects: 21
Study 38307365 — intervention group
Group type: EXPERIMENTAL
Intervention: Ablation (NA group)
Number of subjects: 2204
Study 38307365 — intervention group
Group type: COMPARATOR
Intervention: Drug therapy (NA group)
Number of subjects: 2204
Study 38307365 — intervention group
Group type: EXPERIMENTAL
Intervention: Ablation (non-NA group)
Number of subjects: 2204
Study 38307365 — intervention group
Group type: COMPARATOR
Intervention: Drug therapy (non-NA group)
Number of subjects: 2204
Study 38307421 — intervention group
Group type: EXPERIMENTAL
Intervention: hsCRP ≥2 mg/L
Number of subjects: 232
Study 38307421 — intervention group
Group type: COMPARATOR
Intervention: Spironolactone
Number of subjects: 232
Study 38307421 — intervention group
Group type: COMPARATOR
Intervention: hsCRP <2 mg/L
Number of subjects: 232
Study 38307528 — intervention group
Group type: EXPERIMENTAL
Intervention: EIT-guided PEEP
Number of subjects: 0
Study 38307528 — intervention group
Group type: COMPARATOR
Intervention: Low PEEP/FiO2 table-guided PEEP
Number of subjects: 0
Study 38307529 — intervention group
Group type: EXPERIMENTAL
Intervention: NEWS-1 care (triggered by a high NEWS-2 score ≥5)
Number of subjects: 200
Study 38307529 — intervention group
Group type: COMPARATOR
Intervention: Standard care (initial period before switching to NEWS-1 care)
Number of subjects: 200
Study 38307722 — intervention group
Group type: EXPERIMENTAL
Intervention: MMA embolization within 7 days of burr-hole surgery
Number of subjects: 342
Study 38307722 — intervention group
Group type: COMPARATOR
Intervention: Standard medical care
Number of subjects: 342
Study 38307722 — intervention group
Group type: EXPERIMENTAL
Intervention: MMA embolization
Number of subjects: 342
Study 38307927 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban
Number of subjects: 4930
Study 38307966 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunization with Plasmodium vivax radiation-attenuated sporozoites (PvRAS)
Number of subjects: 12
Study 38307966 — intervention group
Group type: COMPARATOR
Intervention: Mock vaccination
Number of subjects: 12
Study 38307966 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunization with non-irradiated Pv-infected mosquitoes (live sporozoites)
Number of subjects: 12
Study 38308203 — intervention group
Group type: EXPERIMENTAL
Intervention: T2DM patients
Number of subjects: 84
Study 38308203 — intervention group
Group type: EXPERIMENTAL
Intervention: T2DM patients after drug-induced mydriasis
Number of subjects: 84
Study 38308203 — intervention group
Group type: COMPARATOR
Intervention: T1DM patients
Number of subjects: 84
Study 38308203 — intervention group
Group type: COMPARATOR
Intervention: Healthy adults
Number of subjects: 84
Study 38308203 — intervention group
Group type: COMPARATOR
Intervention: Healthy children
Number of subjects: 84
Study 38308227 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil capsules containing n-3 LCPUFAs
Number of subjects: 120
Study 38308227 — intervention group
Group type: COMPARATOR
Intervention: Corn oil (placebo)
Number of subjects: 120
Study 38308248 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic exercise intervention group (8-week, twice-weekly group-based Ai-Chi program)
Number of subjects: 150
Study 38308248 — intervention group
Group type: EXPERIMENTAL
Intervention: On-land exercise group (identical exercise to aquatic group)
Number of subjects: 150
Study 38308248 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 150
Study 38308310 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase angle (PhA) cut-off point of 3.73°
Number of subjects: 31
Study 38308310 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced exercise tolerance defined as performance ≤50% of the predicted value in the six-minute step test (6MST)
Number of subjects: 31
Study 38308310 — intervention group
Group type: EXPERIMENTAL
Intervention: Inflammatory and nutritional status, body composition, peripheral muscle strength
Number of subjects: 31
Study 38308331 — intervention group
Group type: EXPERIMENTAL
Intervention: Program Sustainability Action Planning Model and Training Curricula
Number of subjects: 23
Study 38308331 — intervention group
Group type: COMPARATOR
Intervention: CDC-recommended funding
Number of subjects: 23
Study 38308331 — intervention group
Group type: COMPARATOR
Intervention: American Lung Association smoke-free scores
Number of subjects: 23
Study 38308336 — intervention group
Group type: EXPERIMENTAL
Intervention: K Nearest Neighbors algorithm
Number of subjects: 162
Study 38308336 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning models (various)
Number of subjects: 162
Study 38308377 — intervention group
Group type: EXPERIMENTAL
Intervention: Online nurse-assisted eye screening
Number of subjects: 240
Study 38308377 — intervention group
Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 240
Study 38308453 — intervention group
Group type: EXPERIMENTAL
Intervention: MMR vaccine (with or without varicella vaccine); 5 children with a ≤12-week gap (1-7 weeks) between dupilumab administration and vaccination.
Number of subjects: 9
Study 38308453 — intervention group
Group type: EXPERIMENTAL
Intervention: MMR vaccine (with or without varicella vaccine); 4 children with a >12-week gap after discontinuing dupilumab.
Number of subjects: 9
Study 38308655 — intervention group
Group type: EXPERIMENTAL
Intervention: Izuforant 100 mg twice daily
Number of subjects: 19
Study 38308655 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 38308727 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (ETN)
Number of subjects: 629
Study 38308746 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab (IVR) combined with photodynamic therapy (PDT)
Number of subjects: 90
Study 38308746 — intervention group
Group type: COMPARATOR
Intervention: Intravitreal ranibizumab (IVR) alone (monotherapy)
Number of subjects: 90
Study 38308771 — intervention group
Group type: EXPERIMENTAL
Intervention: bemarituzumab-mFOLFOX6
Number of subjects: 155
Study 38308771 — intervention group
Group type: COMPARATOR
Intervention: placebo-mFOLFOX6
Number of subjects: 155
Study 38308771 — intervention group
Group type: EXPERIMENTAL
Intervention: bemarituzumab-mFOLFOX6 (in FGFR2b-positive GC in ≥10% of tumor cells)
Number of subjects: 155
Study 38309033 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive follow-up (INT)
Number of subjects: 1847
Study 38309033 — intervention group
Group type: COMPARATOR
Intervention: Minimalist follow-up (MIN)
Number of subjects: 1847
Study 38309227 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg 5-HTP daily
Number of subjects: 30
Study 38309228 — intervention group
Group type: EXPERIMENTAL
Intervention: Low arginine levels ≤90.05 μmol/l (n = 86; 37%)
Number of subjects: 231
Study 38309282 — intervention group
Group type: EXPERIMENTAL
Intervention: Tabelecleucel administered intravenously at 2 × 10^6 cells/kg
Number of subjects: 43
Study 38309287 — intervention group
Group type: EXPERIMENTAL
Intervention: Penpulimab plus chemotherapy (paclitaxel 175 mg/m2 and carboplatin)
Number of subjects: 350
Study 38309287 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus chemotherapy (paclitaxel 175 mg/m2 and carboplatin)
Number of subjects: 350
Study 38309492 — intervention group
Group type: EXPERIMENTAL
Intervention: H-VA-10 (vonoprazan 20 mg b.i.d. + amoxicillin 750 mg 4 times a day, 10 days)
Number of subjects: 516
Study 38309492 — intervention group
Group type: EXPERIMENTAL
Intervention: H-VA-14 (vonoprazan 20 mg b.i.d. + amoxicillin 750 mg 4 times a day, 14 days)
Number of subjects: 516
Study 38309492 — intervention group
Group type: EXPERIMENTAL
Intervention: L-VA-10 (vonoprazan 20 mg b.i.d. + amoxicillin 1000 mg b.i.d, 10 days)
Number of subjects: 516
Study 38309519 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral valganciclovir for 6 weeks
Number of subjects: 54
Study 38309519 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 38309610 — intervention group
Group type: EXPERIMENTAL
Intervention: FFR-guided PCI followed by TAVI
Number of subjects: 328
Study 38309610 — intervention group
Group type: COMPARATOR
Intervention: CABG and SAVR
Number of subjects: 328
Study 38309696 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI)
Number of subjects: 0
Study 38309696 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 38309721 — intervention group
Group type: EXPERIMENTAL
Intervention: TIL therapy with lymphodepleting chemotherapy followed by infusion of ex vivo expanded TIL manufactured with IL-2 and agonistic stimulation of CD3 and 4-1BB (urelumab); patients received up to six doses of high-dose IL-2 after TIL infusion.
Number of subjects: 16
Study 38309722 — intervention group
Group type: EXPERIMENTAL
Intervention: Monalizumab 750 mg Q2W plus durvalumab 1500 mg Q4W (cervical cancer; n=15)
Number of subjects: 185
Study 38309722 — intervention group
Group type: EXPERIMENTAL
Intervention: Monalizumab 750 mg Q2W plus durvalumab 1500 mg Q4W (MSS-CRC; n=15)
Number of subjects: 185
Study 38309722 — intervention group
Group type: EXPERIMENTAL
Intervention: Monalizumab 750 mg Q2W plus durvalumab 1500 mg Q4W (NSCLC; n=20)
Number of subjects: 185
Study 38309722 — intervention group
Group type: EXPERIMENTAL
Intervention: Monalizumab 750 mg Q2W plus durvalumab 1500 mg Q4W (ovarian cancer; n=40)
Number of subjects: 185
Study 38309722 — intervention group
Group type: EXPERIMENTAL
Intervention: Monalizumab 750 mg Q2W plus durvalumab 1500 mg Q4W (MSS-endometrial cancer; n=40)
Number of subjects: 185
Study 38309722 — intervention group
Group type: EXPERIMENTAL
Intervention: Monalizumab plus durvalumab
Number of subjects: 185
Study 38309733 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuffed endotracheal tubes (ETTs) of size 4.5; mean ideal cuff volume inflated was 1.7±0.3 ml
Number of subjects: 127
Study 38309733 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuffed endotracheal tubes (ETTs) of size 5.0; mean ideal cuff volume inflated was 1.9±0.3 ml
Number of subjects: 127
Study 38309733 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuffed endotracheal tubes (ETTs) of size 5.5; mean ideal cuff volume inflated was 2.1±0.3 ml
Number of subjects: 127
Study 38309733 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula developed for predicting cuff volume: endotracheal cuff volume (ml) = 1.027 x height (m) + 0.104 x subglottic transverse diameter (mm) - 0.0191
Number of subjects: 127
Study 38309748 — intervention group
Group type: EXPERIMENTAL
Intervention: SCRT followed by four cycles of CAPOX and PD-1 inhibitor (serplulimab)
Number of subjects: 120
Study 38309748 — intervention group
Group type: COMPARATOR
Intervention: Four cycles of capecitabine plus oxaliplatin (CAPOX)
Number of subjects: 120
Study 38309755 — intervention group
Group type: EXPERIMENTAL
Intervention: BioMEL biobank
Number of subjects: 0
Study 38309757 — intervention group
Group type: EXPERIMENTAL
Intervention: tranexamic acid
Number of subjects: 1204
Study 38309757 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1204
Study 38309759 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive, multifaceted intervention in general practice, including extended consultations based on a patient-centred framework.
Number of subjects: 250
Study 38309759 — intervention group
Group type: COMPARATOR
Intervention: Control group continuing care as usual.
Number of subjects: 250
Study 38309761 — intervention group
Group type: EXPERIMENTAL
Intervention: CSA-coated ETT (CeraShield N8 Pharma)
Number of subjects: 0
Study 38309761 — intervention group
Group type: COMPARATOR
Intervention: ETT with subglottic secretion drainage (Taper Guard, Covidien)
Number of subjects: 0
Study 38309828 — intervention group
Group type: EXPERIMENTAL
Intervention: High temperatures (measured as maximum air temperature)
Number of subjects: 5039
Study 38309829 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-quantity lipid-based nutrient supplements (SQ-LNS) during pregnancy and 6 months postpartum
Number of subjects: 966
Study 38309829 — intervention group
Group type: COMPARATOR
Intervention: Control group (iron and folic acid (IFA) during pregnancy and placebo postpartum or multiple micronutrients (MMNs) during pregnancy and postpartum)
Number of subjects: 966
Study 38309829 — intervention group
Group type: EXPERIMENTAL
Intervention: SQ-LNS
Number of subjects: 966
Study 38309831 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 infection (Cohort-1)
Number of subjects: 488
Study 38309831 — intervention group
Group type: COMPARATOR
Intervention: Milk bank donors (Cohort-2)
Number of subjects: 488
Study 38309831 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination (Cohort-3)
Number of subjects: 488
Study 38310035 — intervention group
Group type: EXPERIMENTAL
Intervention: Domvanalimab 1200 mg plus zimberelimab 360 mg plus platinum-doublet chemotherapy (PT)
Number of subjects: 720
Study 38310035 — intervention group
Group type: COMPARATOR
Intervention: Pembrolizumab 200 mg plus PT
Number of subjects: 720
Study 38310035 — intervention group
Group type: EXPERIMENTAL
Intervention: Zimberelimab 360 mg plus PT
Number of subjects: 720
Study 38310163 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirzepatide 5 mg
Number of subjects: 636
Study 38310163 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirzepatide 10 mg
Number of subjects: 636